JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 50(2016) N 1 p. 37-42; DOI 10.1134/S0026893316010210 Full Text

E.G. Varlamova*, S.V. Novoselov

Methods to Biosynthesize Mammalian Selenocysteine-Containing Proteins in vitro

Institute of Cell Biophysics, Russian Academy of Sciences, Pushchino, Moscow oblast, 142290 Russia

*1928lv@mail.ru
Received - 2015-05-12; Accepted - 2015-06-03

The main problem in studying mammalian selenocysteine-containing proteins is that the proteins are difficult to obtain in a recombinant form because the amino acid selenocysteine (Sec), which is their component, is encoded by TGA, which is one of the stop codons. When only the open reading frame of a target protein is cloned in a plasmid, translation is prematurely terminated at the TGA codon. An intricate natural mechanism allows the codon to be recognized as a selenocysteine codon and involves various cis- and trans-acting factors, such as the selenocysteine insertion sequence (SECIS), mRNA secondary structure, selenocysteine tRNA Sec-tRNA [Ser]Sec, SECIS-binding protein 2 (SBP2), selenocysteine-specific elongation factor EFsec, and others. Generation of recombinant selenoproteins in preparative amounts directly depends on the expression levels of the cis- and trans-acting transcription and translation factors to further complicate the problem, and cysteine homologs of selenoproteins are consequently used in many studies. Several methods designed to express mammalian selenoproteins in vitro are considered in the review.

selenocysteine, mammalian selenocysteine-containing proteins, selenoprotein synthesis



JMB-FOOTER RAS-JOURNALS